A Cigna (NYSE: CI) analysis has found that 98.4 percent of Cigna
Pharmacy Management customers treated with Harvoni for hepatitis C
genotype 1 achieved a sustained virologic response (SVR12), meaning they
are considered to be cured of hepatitis. The latest analysis continues
Cigna's efforts to understand how prescription drugs perform in the
“real world” and deliver solutions that generate quantifiable
improvements in clinical outcomes and affordability that meet or exceed
results seen in clinical trials.
“Our specialty approach focuses on delivering better clinical outcomes
and affordability. We focus on the whole customer, collaboration with
physicians, and comprehensive customer engagement. This approach goes
well beyond just negotiating competitive drug price rates by creating
real incentive alignment with drug manufacturers to meet or exceed
expected clinical outcomes,” said Christopher Bradbury, senior vice
president, integrated clinical and specialty drug solutions for Cigna
Pharmacy Management. “Our connected care approach drives meaningful
improvement in clinical results and affordability and -- as we see with
hepatitis C -- delivers powerful, real-world benefits for customers and
clients.”
Cigna's connected care strategy for hepatitis C includes:
-
extensive clinical management to ensure safety and appropriateness;
-
comprehensive clinical counseling for all customers regardless of the
pharmacy they use;
-
a preferred drug approach including development of an innovative outcomes-based
incentive with Gilead Sciences (drug manufacturer);
-
physician engagement to support evidence-based decision-making; and,
-
Cigna's leading specialty pharmacy.
Additional insights from the analysis show:
-
98.1 percent SVR12 for people with cirrhosis and 98.5 percent SVR12
for those without cirrhosis.
-
98.4 percent SVR12 for those with F0-F2 Metavir score, and 98.3
percent SVR12 for people with F3-F4 Metavir score. A Metavir score is
a system used to assess the health of the liver.
-
99.3 percent SVR12 for customers who used Cigna's Specialty Pharmacy.
Cigna also found that its connected care approach to working with
physicians has helped its customers receive the preferred drug therapy
when clinically appropriate, as well as appropriate length of treatment
according to evidence-based standards, helping to improve health and
affordability:
-
99.0 percent of customers with hepatitis C genotype 1 were treated
with Harvoni since implementation of Cigna's preferred drug approach.
-
100 percent of customers achieved SVR12 when Cigna engaged physicians
in aligning the length of therapy (8, 12 or 24 weeks) with
evidence-based protocols.
About Cigna
Cigna Corporation (NYSE: CI) is a global health service company
dedicated to helping people improve their health, well-being and sense
of security. All products and services are provided exclusively by or
through operating subsidiaries of Cigna Corporation, including
Connecticut General Life Insurance Company, Cigna Health and Life
Insurance Company, Life Insurance Company of North America and Cigna
Life Insurance Company of New York. Such products and services include
an integrated suite of health services, such as medical, dental,
behavioral health, pharmacy, vision, supplemental benefits, and other
related products including group life, accident and disability
insurance. Cigna maintains sales capability in 30 countries and
jurisdictions, and has more than 88 million customer relationships
throughout the world. To learn more about Cigna®, including links to
follow us on Facebook or Twitter, visit www.cigna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150717005479/en/
Copyright Business Wire 2015